Skip NavigationSkip to Content

Benzosuberene and Tetracyclic Analogues as Colchicine Site Inhibitors of Tubulin Polymerization

  1. Author:
    VanNatta, Jennifer M
    Carlson, Graham J
    Niu, Haichan
    Bai, Ruoli
    Wanniarachchi, Hashini I
    Schuetze, Regan
    Trawick, Mary Lynn
    Hamel,Ernest
    Mason, Ralph P [ORCID]
    Pinney, Kevin G [ORCID]
  2. Author Address

    Department of Chemistry and Biochemistry, Baylor University, One Bear Place, No. 97348, Waco, Texas 76798-7348, United States., Molecular Pharmacology Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Frederick National Laboratory for Cancer Research, National Cancer Institute, National Institutes of Health, Frederick, Maryland 21702, United States., Department of Radiology, The University of Texas Southwestern Medical Center, 5323 Harry Hines Boulevard, Dallas, Texas 75390-9058, United States.,
    1. Year: 2025
    2. Date: Jun 12
    3. Epub Date: 2025 05 26
  1. Journal: ACS Medicinal Chemistry Letters
    1. 16
    2. 6
    3. Pages: 1098-1107
  2. Type of Article: Article
  1. Abstract:

    Colchicine site inhibitors of tubulin polymerization function as antiproliferative anticancer agents, with certain inhibitors demonstrating a dual mechanism of action as tumor-selective vascular disrupting agents (VDAs). Our previous studies yielded potent benzosuberene-based colchicine site inhibitors of tubulin polymerization. To expand structure-activity correlations, the seven-membered fused ring and the pendant ring were modified to generate a series of new compounds, 11 being strong inhibitors (IC50 = 5 µM) of tubulin polymerization. Structural modifications introduced a second benzylic olefin and, separately, a nitrogen atom to the fused seven-membered ring, along with conversion to unique tetracyclic fused ring systems. Two of the active inhibitors were synthetically converted to corresponding phosphate prodrug salts to increase aqueous solubility for in vivo studies. In a preliminary study of VDA efficacy, these prodrugs caused blood flow disruption in mice, as revealed by bioluminescence imaging with histological confirmation. The most effective analogues from this series offer promise as cancer therapeutic agents. © 2025 American Chemical Society.

    See More

External Sources

  1. DOI: 10.1021/acsmedchemlett.5c00129
  2. PMID: 40529069
  3. PMCID: PMC12169467

Library Notes

  1. Fiscal Year: FY2024-2025
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel